|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study显示文摘 | Giancarlo Agnelli Gualberto Gussoni Carlo Bianchini Melina Verso Mario Mandalà Luigi Cavanna Sandro Barni Roberto Labianca Franco Buzzi Giovanni Scambia Rodolfo Passalacqua Sergio Ricci Giampietro Gasparini Vito Lorusso Erminio Bonizzoni Maurizio Tonato | 2009 | Lancet Oncology2009，，10： | 1 |
| 2 | Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The 'GISCAD-altemating schedule' study findings显示文摘 | Mario Mandala Sandro Barni Irene Floriani | 2009 | Europeanjoumal of Cancer2009，45，1： | 1 |
| 3 | Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel显示文摘 | Fausto Petrelli Karen Borgonovo Sandro Barni | 2010 | Expert Opinion on Pharmacotherapy2010，，8： | 1 |
| 4 | Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials显示文摘 | Fausto Petrelli Karen Borgonovo Mary Cabiddu Sandro Barni | 2012 | Clinical Lung Cancer2012，，2： | 1 |
| 5 | Chemotherapy-associated thromboembolic risk in cancer outpatients and effect ofnadroparin thromboprophylaxis: Results of a retrospective analysis of thePROTECHT study显示文摘 | Sandro Barni Roberto Labianca Giancarlo Agnelli | 2011 | J Transl Med2011，9，： | 1 |
| 6 | The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis显示文摘 | Fausto Petrelli Andrea Coinu Karen Borgonovo Mary Cabiddu Mara Ghilardi Veronica Lonati Sandro Barni | 2014 | Breast Cancer Research and Treatment2014，，2： | 1 |
| 7 | FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials显示文摘 | Fausto Petrelli Karen Borgonovo Mary Cabiddu Mara Ghilardi Veronica Lonati Federica Maspero Maria Grazia Sauta Giordano Domenico Beretta Sandro Barni | 2013 | Clinical Colorectal Cancer2013，，： | 1 |
| 8 | A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score显示文摘 | Melina Verso Giancarlo Agnelli Sandro Barni Giampietro Gasparini Roberto LaBianca | 2012 | Internal and Emergency Medicine2012，，： | 1 |
| 9 | FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials显示文摘 | Giordano Domenico Beretta Fausto Petrelli Sergio Stinco Mary Cabiddu Mara Ghilardi Michela Squadroni Karen Borgonovo Sandro Barni | 2013 | Medical Oncology2013，，1： | 1 |
| 10 | Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis显示文摘 | Nicola Silvestris Mario Scartozzi Giusi Graziano Daniele Santini Vito Lorusso Evaristo Maiello Sandro Barni Saverio Cinieri Fotios Loupakis Salvatore Pisconti Anna Elisabetta Brunetti Giuseppe Palasciano Vincenzo Ostilio Palmieri Michela Del Prete Emanuel | 2015 | Expert Opinion on Biological Therapy2015，，2： | 1 |
| 11 | Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials显示文摘BACKGROUND:Progression-free survival(PFS)has not been extensively investigated as a surrogate for survival in the firstline treatments of pancreatic cancer.The aim of this review was to evaluate PFS as a potential surrogate endpoint for overall survival(OS)in advanced pancreatic cancer in trials comparing poly-chemotherapy to gemcitabine alone. | Fausto Petrelli Andrea Coinu Karen Borgonovo Mary Cabiddu Sandro Barni | 2015 | Hepatobiliary & Pancreatic Diseases International2015，14，2： | 1 |
| 12 | Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial显示文摘 | Stefano Cascinu Rossana Berardi Roberto Labianca Salvatore Siena Alfredo Falcone Enrico Aitini Sandro Barni Francesco Di Costanzo Elisa Dapretto Giuseppe Tonini Chiara Pierantoni Salvatore Artale Silvia Rota Irene Floriani Mario Scartozzi Alberto Zaniboni | 2008 | Lancet Oncology2008，，1： | 1 |
| 13 | FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study显示文摘 | Alberto Zaniboni Enrico Aitini Sandro Barni Daris Ferrari Stefano Cascinu Vincenzo Catalano Giuseppe Valmadre Domenica Ferrara Enzo Veltri Claudio Codignola Roberto Labianca | 2012 | Cancer Chemotherapy and Pharmacology2012，，6： | 1 |
| 14 | Which strategy after first-line therapy in advanced colorectal cancer?显示文摘Second-line therapy for advanced colorectal cancer is an integral part of the treatment strategy that needs to be set from the beginning for each patient, bearing in mind the expected toxicities of chosen treatments, the patient's clinical condition, comorbidities, preferences, the aims of the treatment and the molecular status. Furthermore, the distinction between lines of therapy is no longer absolute. The perspective of 'continuum of care' includes switching chemotherapy prior to disease progression, maintenance therapy, drug 'holidays' if needed, surgical resection of metastases in selected patients, and seems to allow a tailored treatment, in which patients are more likely to benefit from exposure to all active agents, which is known to correlate with overall survival. The scenario of second-line treatment has changed dramatically over the years and could currently benefit from several options including chemotherapy with a single agent or in combination and the addition of molecular-targeted agents developed in the last decade, such as epidermal growth factor receptor antibodies(cetuximab, panitumumab) and vascular endothelial growth factor-targeting agents(bevacizumab, aflibercept), with the possibility of bevacizumab use even beyond first progression. The purpose of this review is to summarize the most important scientific data supporting the use of chemotherapy and the new biologic agents in the second-line setting in advanced colorectal cancer. | Coinu Andrea Petrelli Fausto Borgonovo Karen Francesca Cabiddu Mary Ghilardi Mara Lonati Veronica Barni Sandro | 2014 | World Journal of Gastroenterology2014，20，27： | 1 |
| 15 | Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies显示文摘 | Fausto Petrelli Karen Borgonovo Mary Cabiddu Mara Ghilardi Sandro Barni | 2012 | Expert Opinion on Drug Safety2012，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员